Vertaling van "alleging that sandoz may have " (Nederlands → Frans) :

In October 2009, the European Commission, together with the French competition authority, searched the French offices of Sandoz, alleging that Sandoz may have entered into anticompetitive price coordination practices with other generic pharmaceuticals companies and via the French trade association for generic pharmaceuticals companies.
En octobre 2009, La Commission européenne, de concert avec le Conseil de la concurrence, a perquisitionné les bureaux de Sandoz en France, arguant du fait que Sandoz pourrait avoir conclu des ententes sur les prix avec d’autres sociétés pharmaceutiques et par le biais de l’Association Française des Génériques.

Average Wholesale Price litigation Claims have been brought against various pharmaceutical companies, including NPC and certain Sandoz entities, alleging that they fraudulently overstated the Average Wholesale Price and “best price”, which are, or have been, used by the US federal and state governments in the calculation of, respectively, Medicare reimbursements and Medicaid rebates. In some cases, motions to dismiss or (cross-) motions for summary judgment in other cases have been made and are currently pending.
Litige concernant le prix de gros moyen Des plaintes ont été déposées contre différentes sociétés pharmaceutiques, dont NPC et certaines entités de Sandoz, au motif que celles-ci auraient frauduleusement exagéré le prix de gros moyen (average wholesale price [AWP]) et le «meilleur prix» qui sont ou ont été utilisés par le gouvernement fédéral américain et des gouvernements d’Etat pour calculer les remboursements des médicaments dans le cadre du programme Medicare et les rabais dans celui de Medicaid.

Average Wholesale Price litigation Claims have been brought against various pharmaceutical companies, including NPC and certain Sandoz entities, alleging that they fraudulently overstated the Average Wholesale Price and “best price”, which are, or have been, used by the US federal and state governments in the calculation of, respectively, Medicare reimbursements and Medicaid rebates. In some cases, motions to dismiss or (cross-) motions for summary judgment have been made and are currently pending.
Litige concernant le prix de gros moyen Des plaintes ont été déposées contre différentes sociétés pharmaceutiques, dont NPC et certaines entités de Sandoz, au motif que celles-ci auraient frauduleusement exagéré le prix de gros moyen (average wholesale price [AWP]) et le «meilleur prix» qui sont ou ont été utilisés par le gouvernement fédéral américain et des gouvernements d’Etat pour calculer les remboursements des médicaments dans le cadre du programme Medicare et les rabais dans celui de Medicaid.

Average Wholesale Price litigation Claims have been brought against various pharmaceutical companies, including NPC and certain Sandoz entities, alleging that they fraudulently overstated the Average Wholesale Price and “best price”, which are, or have been, used by the US federal and state governments in the calculation of, respectively, Medicare reimbursements and Medicaid rebates.
Litige concernant le prix de gros moyen Des plaintes ont été déposées contre différentes sociétés pharmaceutiques, dont NPC et certaines entités de Sandoz, au motif que celles-ci auraient frauduleusement exagéré le prix de gros moyen (average wholesale price [AWP]) et le «meilleur prix» qui sont ou ont été utilisés par le gouvernement fédéral américain et des gouvernements d’Etat pour calculer les remboursements des médicaments dans le cadre du programme Medicare et les rabais dans celui de Medicaid.

Average Wholesale Price litigation Claims have been brought against various pharmaceutical companies, including Novartis subsidiaries, alleging that they have fraudulently overstated the Average Wholesale Price and “best price”, which are, or have been, used by the US federal and state governments in the calculation of, respectively, Medicare reimbursements and Medicaid rebates.
Litige concernant le prix de gros moyen Des plaintes ont été déposées contre différentes sociétés pharmaceutiques, dont des filiales de Novartis, prétendant que celles-ci ont frauduleusement exagéré le prix de gros moyen (average wholesale price [AWP]) et le «meilleur prix» qui sont ou ont été utilisés par le gouvernement américain et des gouvernements d’Etat pour calculer les remboursements des médicaments dans le cadre du programme Medicare et les rabais dans celui de Medicaid.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

The speed of circulation of the information and of the response to that information is essential, given that the alerts relate to problems that may have serious or even life-threatening consequences for patients.
The speed of circulation of the information and of the response to that information is essential, given that the alerts relate to problems that may have serious or even life-threatening consequences for patients.

As a consequence, Novartis may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow.
Par conséquent, Novartis pourrait faire l’objet de jugements ou être impliqués dans le règlement de plaintes susceptibles d’affecter ses résultats opérationnels ou ses flux de trésorerie.

serious adverse events associated with the collection, testing, processing, storage and distribution of blood or blood components that may have an effect on their quality or safety ●● Collecting and evaluating information about
serious adverse events associated with the collection, testing, processing, storage and distribution of blood or blood components that may have an effect on their quality or safety ●● Collecting and evaluating information about

Impairment testing under IFRS may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Group’s financial results.
Les tests de dépréciation menés selon les normes IFRS peuvent conduire à des pertes de valeur potentiellement importantes à l’avenir, lesquelles pourrait avoir des répercussions matériellement négatives sur les résultats financiers du Groupe.